Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC M4PVOWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXe1XGFwcW6qaXLpeJMhfGinIG\FS2YucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJGhWXkWFcx?= MUWxPFYzODN6Mh?=
HUVEC NXXTe3RCU2mwYYPlJIF{e2G7 NXPUO2VjcW6qaXLpeJMhXkWJRj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDWSWdHWi1{IHnuJGhWXkWFIHPlcIx{KHerdHigZY4hUUN3MDDv[kDjkLx6IH7N MoHuNVg3OjB|OEK=
MM MmDCT4lv[XOnIHHzd4F6 NHjXdIVqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIH\seFE> MVixO|E3PDN|Mh?=
MM.1S M3LmfWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{XK[FExKM7:Zz;tUC=> MYLpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? NFmz[3oyPzF4NEOzNi=>
MM.1R MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NY[yNVk5OTBizsznM41N M1HlN4lvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq NXHCS4lvOTdzNkSzN|I>
RPMI NYrIU|JqT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mm\tNVAh|rypL33M NV\MSGZucW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MWCxO|E3PDN|Mh?=
Dox40 NFniWIFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NH\qNZMyOCEQvHevcWw> M13oXolvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq MV6xO|E3PDN|Mh?=
INA-6 NYLKV5FmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1fLUlExKM7:Zz;tUC=> NX\KVZM{cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= MkW3NVcyPjR|M{K=
OPM2 MojHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXrWWXl7OTBizsznM41N M1LCbYlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq MVexO|E3PDN|Mh?=
U266 NIL3N2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NGqxflIyOCEQvHevcWw> NFTtUYhqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= M{PlSFE4OTZ2M{Oy
MM.1S MV;jfZRwfG:6aXPpeJkh[XO|YYm= NHGxR28zOCEQvHevcWw> NGn5cGJqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs NEfVO3cyPzF4NEOzNi=>
MM.1R MYnjfZRwfG:6aXPpeJkh[XO|YYm= MVuyNEDPxGdxbVy= Mlq3bY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= NGSxXFEyPzF4NEOzNi=>
RPMI NF7SUIZkgXSxdH;4bYNqfHliYYPzZZk> NXLzSlBYOjBizsznM41N NITiT29qdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs NEHjVXYyPzF4NEOzNi=>
Dox40 NUPoVZhb[3m2b4TvfIlkcXS7IHHzd4F6 NHPTdlgzOCEQvHevcWw> MXjpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MX2xO|E3PDN|Mh?=
INA-6 NInGb4xkgXSxdH;4bYNqfHliYYPzZZk> NUmwfYtMOjBizsznM41N NVS0Ond7cW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> NUfrOGd{OTdzNkSzN|I>
OPM2 MYTjfZRwfG:6aXPpeJkh[XO|YYm= MoTlNlAh|rypL33M Mn3JbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= MoPqNVcyPjR|M{K=
U266 NGLQdIRkgXSxdH;4bYNqfHliYYPzZZk> MnjENlAh|rypL33M M2XRbolvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NXX5PIN4OTdzNkSzN|I>
MM.1S NIT5WVZHfW6ldHnvckBie3OjeR?= Mmfhd5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w M37yN|E4OTZ2M{Oy
MM.1R M2rUdWZ2dmO2aX;uJIF{e2G7 MW\zeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? NEnnW3QyPzF4NEOzNi=>
Dox40 MWHGeY5kfGmxbjDhd5NigQ>? NF3kfXB{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= M3;FS|E4OTZ2M{Oy
OPM2 M2nGTmZ2dmO2aX;uJIF{e2G7 M{WzWZN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= M1zEPVE4OTZ2M{Oy
HBMEC MnrLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGfyZVN,OTBizszN M2LjRmROW09? NEXzR4NKSzVyPUGg{txO Ml7iNlExQDF4NU[=
HBMEC M4TQNmZ2dmO2aX;uJIF{e2G7 MWL+NUDPxE1? Mn;xSG1UVw>? NXO4b4lq[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= NH;XfokzOTB6MU[1Oi=>
HBMEC NHLiVphHfW6ldHnvckBie3OjeR?= NV3lSJBmhjFizszN NH7jN3dFVVOR MkLn[Il{enWydIOgeIhmKFKjcz3SZYYuTVKNIIDheIh4[XlidHjyc5VocCCmZXPy[YF{\WRicHjvd5Bpd3K7bHH0[YQhVUWNMT:yJIFv\CCHUluxM|I> NVXa[HhzOjFyOEG2OVY>
HBMEC M37qTWZ2dmO2aX;uJIF{e2G7 NH\ldmF,OjBizszN NU\5UGNuTE2VTx?= NWLSUHhE\Gm|coXweJMhPTBnIH;mJJR2[mViZn;ycYF1cW:wIHH0JFEh|ryP MVGyNVA5OTZ3Nh?=
MDA-MB-231 M2TVZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX;HT3ZxhjFyIN88US=> NWL5NmMzTE2VTx?= MkP5TWM2OD13IN88US=> M1fsTFIyODhzNkW2
MDA-MB-231 NEXrSHNHfW6ldHnvckBie3OjeR?= MmXUNE42KM7:TR?= M3WzSGROW09? MmTJbY5pcWKrdIOgeIhmKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfS=> NFnGXFUzOTB6MU[1Oi=>
MDA-MB-231 NFLsUFdHfW6ldHnvckBie3OjeR?= M1HhOFUh|ryP MnnaSG1UVw>? MWnpcoR2[2W|IHGgZ4VtdC2leXPs[UBienKnc4S= MXyyNVA5OTZ3Nh?=
J82 M2nIeYN6fG:2b4jpZ4l1gSCjc4PhfS=> NI\xVW5,OTBizszN NW\IeFU5TE2VTx?= NX3MbFN{UUN3ME2yOE42PyEQvF2= NGjBN3IzOTV{OUmwNC=>
T24 M{K2TYN6fG:2b4jpZ4l1gSCjc4PhfS=> NXnlR2ZxhjFyIN88US=> MYTEUXNQ NUDuPWNLUUN3ME21Nk41PSEQvF2= M3fxPVIyPTJ7OUCw
HT1376 NHHGWIZkgXSxdH;4bYNqfHliYYPzZZk> MX3+NVAh|ryP MWPEUXNQ MXrJR|UxRTJ6LkKxJO69VQ>? M1[4S|IyPTJ7OUCw
RT4 Mmr4Z5l1d3SxeHnjbZR6KGG|c3H5 NUPiU5hUhjFyIN88US=> NHHoVVhFVVOR M4LOcGlEPTB;NT6xOEDPxE1? NIK1So0zOTV{OUmwNC=>
CRL1749 M1KxOoN6fG:2b4jpZ4l1gSCjc4PhfS=> NVK5UpNJhjFyIN88US=> NF34VIhFVVOR M1\GN2lEPTB;MkKuOlkh|ryP MoXJNlE2Ojl7MEC=
HTB9 M{OwU4N6fG:2b4jpZ4l1gSCjc4PhfS=> MVr+NVAh|ryP MVrEUXNQ NY\xeZl3UUN3ME2xNU45PCEQvF2= MnXCNlE2Ojl7MEC=
Sup NF:zRXVkgXSxdH;4bYNqfHliYYPzZZk> MXL+NVAh|ryP NELUVpZFVVOR NG\SeJZKSzVyPUWzMlMzKM7:TR?= NFrEc5gzOTV{OUmwNC=>
HTB3 NF:zWWNkgXSxdH;4bYNqfHliYYPzZZk> NUPCN3F3hjFyIN88US=> M33GbWROW09? MVTJR|UxRTF2LkG2JO69VQ>? MX:yNVUzQTlyMB?=
CEC M{XkPWZ2dmO2aX;uJIF{e2G7 MUL+NVAh|rypL33M MXvEUXNQ MmXr[I94di2{ZXf1cIF1\XNiVlXHSkBt\X[nbIO= MUWyNVYzODh{Mh?=
RPE NYTrUYdWTnWwY4Tpc44h[XO|YYm= NI\Feo1,OTBizsznM41N M1H3TmROW09? M1:zNYRwf25vcnXneYxifGW|IG\FS2YhdGW4ZXzz MmXmNlE3OjB6MkK=
CEC M3rWe2Z2dmO2aX;uJIF{e2G7 NIK1SlR,PSEQvHevcWw> M1\vbWROW09? M4jWfYJtd2OtczDlcoRwfGinbHnhcEBk\WyuIH3p[5JifGmxbh?= MXqyNVYzODh{Mh?=
5637 NE\zbmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NX7rPWpDTE2VTx?= MV\JR|UxRTF3LkFihKnPxE1? NYXOOYU1OjN6OEe2NFU>
J82 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MmDaSG1UVw>? Mn:2TWM2OD1zOD605qCK|ryP MYeyN|g5PzZyNR?=
5637 M3jZd2F2fG:yaHHnfUBie3OjeR?= M4\sUFIxKM7:TR?= MVXEUXNQ MkTUeJJq\2encoOgeIhmKGG3dH;wbIFocWNicILvZ4V{ew>? M3rURVI{QDh5NkC1
J82 NIT3PYVCfXSxcHjh[5kh[XO|YYm= MWCyNEDPxE1? NVnhcI92TE2VTx?= NHXtVId1emmpZ3Xyd{B1cGViYYX0c5Bp[WerYzDwdo9k\XO| NIrMenozOzh6N{[wOS=>
5637 NVnEfIZVTnWwY4Tpc44h[XO|YYm= NIf0WHQzOCEQvF2= NHvJR2ZFVVOR NYPHZ3NpcW6mdXPld{BtgXOxc3;tZYwu\GWyZX7k[Y51KG6nY4Lvd4l{ M1TGTlI{QDh5NkC1
J82 MmDCSpVv[3Srb36gZZN{[Xl? NWnjUXhGOjBizszN M37WUWROW09? Ml64bY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz NYHOSHQyOjN6OEe2NFU>
5637 NULO[pc3TnWwY4Tpc44h[XO|YYm= MnixNlAh|ryP NWHhZnVWTE2VTx?= NHT3boNqdmS3Y3XzJIx6e2:|b33lJIFtfGW{YYTpc44h[W6mIHnubIljcXS|IFPCJIFkfGm4aYT5 MVGyN|g5PzZyNR?=
J82 M3\0VWZ2dmO2aX;uJIF{e2G7 M2TRfFIxKM7:TR?= NUXkNVU3TE2VTx?= NEXPPVNqdmS3Y3XzJIx6e2:|b33lJIFtfGW{YYTpc44h[W6mIHnubIljcXS|IFPCJIFkfGm4aYT5 NFfLTVIzOzh6N{[wOS=>
KATO-II M3zMXWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHzscIs2KM7:TR?= M2L0emROW09? Mo\WZoxw[2u|IIDyc4xq\mW{YYTpc44> M4nVdVI2OjR7NUW3
OCUM-2M NIHJepJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MWO1JO69VQ>? NGCxeXhFVVOR M3i4UYJtd2OtczDwdo9tcW[ncnH0bY9v M1jVT|I2OjR7NUW3
SNU-16 MoOyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MWK1JO69VQ>? M1jY[WROW09? NGjmR25jdG:la4OgdJJwdGmoZYLheIlwdg>? MlrqNlUzPDl3NUe=
HSC-39 MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGTpeFU2KM7:TR?= NGrVOGtFVVOR M1q3XIJtd2OtczDwdo9tcW[ncnH0bY9v MnvLNlUzPDl3NUe=
KATO-II MUDjfZRwfG:6aXPpeJkh[XO|YYm= NX7RTJJShjFyIN88US=> MXXEUXNQ MWrJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? NUnGT3FFOjV{NEm1OVc>
OCUM-2M MoH4Z5l1d3SxeHnjbZR6KGG|c3H5 NV61NGhUhjFyIN88US=> M1P6SGROW09? MmXjTWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? MnzrNlUzPDl3NUe=
SNU-16 M1;0eoN6fG:2b4jpZ4l1gSCjc4PhfS=> NHHRfZd,OTBizszN NWi3W5VITE2VTx?= MYPJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? MlXzNlUzPDl3NUe=
HSC-39 MXzjfZRwfG:6aXPpeJkh[XO|YYm= MlfYglExKM7:TR?= MVLEUXNQ NXfifXl1UUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= MUmyOVI1QTV3Nx?=
NIH 3T3 MX7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVr+NVAh|ryP M1H1WGROW09? MmHibY5pcWKrdIOgZ4VtdCCpcn;3eIgh[W6mIHPvcI9vgSCob4LtZZRqd25? MVKyOVI1QTV3Nx?=
KATO-III MlzaSpVv[3Srb36gZZN{[Xl? Mlf1NUDPxE1? MVfEUXNQ M{jqeolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= MmLZNlUzPDl3NUe=
OCUM-2M NUHzfHpUTnWwY4Tpc44h[XO|YYm= MXyxJO69VQ>? M3LMS2ROW09? NYnkZol1cW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> MnO0NlUzPDl3NUe=
KATO-III M1X4R2Fxd3C2b4Ppd{Bie3OjeR?= MnnuNUDPxE1? Mni4SG1UVw>? MonkbY5lfWOnczDhdI9xfG:|aYO= NX6zRYlKOjV{NEm1OVc>
OCUM-2M NIfzVJlCeG:ydH;zbZMh[XO|YYm= M4TYfFEh|ryP Ml;DSG1UVw>? NHi4UlRqdmS3Y3XzJIFxd3C2b4Ppdy=> MV:yOVI1QTV3Nx?=
KATO-III MYnGeY5kfGmxbjDhd5NigQ>? M3rESFEh|ryP NUXNV2tWTE2VTx?= MlLLbY5pcWKrdIOgSmdHWjJicHjvd5Bpd3K7bHH0bY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[{Bud2ynY4Xs[ZM> NWLVOWhyOjV{NEm1OVc>

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID